Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tirzepatide
- Development stage
- Approved
- Lead developer
- Eli Lilly
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Tirzepatide is a synthetic peptide drug administered as a once-weekly subcutaneous injection. It acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide 1 (GLP-1) receptor, mimicking the action of these natural incretin hormones. By activating both receptors, tirzepatide increases insulin secretion, suppresses appetite, slows gastric emptying, and enhances satiety. It is approved for use in adults with type 2 diabetes to improve glycemic control (as Mounjaro), for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (as Zepbound), and for moderate-to-severe obstructive sleep apnea in patients with obesity. Tirzepatide has demonstrated superior efficacy in glycemic control and weight loss compared to selective GLP-1 receptor agonists[1][2][4][5][7].
- Brand names
- MounjaroZepbound
- Other names
- none
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on tirzepatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tirzepatide.